Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance

Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance

BackgroundFamilial partial lipodystrophy type 3 (FPLD3) is a very rare autosomal dominant genetic disorder which is caused by mutations in the peroxisome proliferator activated receptor gamma (PPARG) gene. It is characterized by a partial loss of adipose tissue leading to subnormal leptin secretion...

Full description

Bibliographic Details
Main Authors: Vaia Lambadiari, Aikaterini Kountouri, Eirini Maratou, Stavros Liatis, George D. Dimitriadis, Fredrik Karpe
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Endocrinology
Subjects:
diabetes mellitus
hypertriglyceridemia
metreleptin
familial partial lipodystrophy
PPARG
insulin resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.684182/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.684182/full

Similar Items